Current and Future Treatments for Takayasu Arteritis: Toward Cardiovascular Risk Modification.

34 In the TAKT study (Takayasu Arteritis Treated With Tocilizumab), a double-blind phase 3 RCT, there was a favorable trend toward tocilizumab over placebo for time to relapse, the primary end point; the relapse rate was higher in the placebo arm (53% versus 23%). 22 In the longer open-label follow-up in which all patients received tocilizumab for 96 weeks, disease stabilization was observed in 70% and improvement was seen in 20%. 35 One challenge is that routinely measured acute-phase reactants become unreliable indicators of disease flare in patients receiving tocilizumab.

also in 993 other papers